New Lung Cancer Drug Extends Lives by 15%

Patients with advanced lung cancer are living months longer thanks to a promising new drug that could change how doctors fight the disease.

Ivonescimab, developed by China-based company Akeso, helped patients with advanced squamous non-small cell lung cancer live an average of 27.9 months compared to 23.7 months with existing treatment. That's an extra 4.2 months with loved ones, making memories and celebrating milestones.

The study involved 532 patients in China with stage 3 or 4 non-small cell lung cancer, one of the most aggressive forms of the disease. All patients received chemotherapy, but those who also got ivonescimab saw their risk of death drop by 34% compared to those receiving the current standard immunotherapy called Tevimbra.

What makes ivonescimab special is how it works. The drug is a bispecific antibody, meaning it attacks cancer on two fronts by targeting both PD-1 and VEGF proteins that help tumors grow and spread.

Dr. David Spigel, chief medical officer at Nashville's Sarah Cannon Research Institute, called the results a step forward while noting that more research is needed. The drug's effectiveness in diverse global populations still needs confirmation through ongoing trials.

The Bright Side

This breakthrough comes at a critical time. Lung cancer remains one of the deadliest cancers worldwide, and squamous non-small cell lung cancer is particularly challenging to treat. Every additional month of life gives patients precious time with family and a better shot at seeing new treatments emerge.

Akeso believes ivonescimab could become a new standard of care for patients fighting this aggressive disease. The company is currently running global trials comparing the drug directly to Keytruda, Merck's widely used cancer immunotherapy, which could pave the way for approval in the United States and other countries.

For the hundreds of thousands of people diagnosed with advanced lung cancer each year, this research offers something invaluable: hope backed by real science.